The management and treatment of children with Fabry disease: A United States-based perspective

Robert J. Hopkin, John L. Jefferies, Dawn A. Laney, Victoria H. Lawson, Michael Mauer, Matthew R. Taylor, William R. Wilcox

Research output: Contribution to journalReview article

27 Citations (Scopus)

Abstract

Fabry disease is an inherited X-linked disorder that presents during childhood in male and female patients. Young patients may initially experience pain, hypohidrosis, and gastrointestinal symptoms. Other manifestations of Fabry disease, such as renal and cardiac disease, manifest later in adolescence or adulthood. In the pediatric population, renal damage is typically subclinical and identifiable only through biopsy. Specialists from the United States with expertise in Fabry disease convened during 2013-2014 in order to develop these consensus guidelines about the management and treatment of children with Fabry disease. The presence of symptoms in boys and girls of any age is an indication to begin therapy. Early treatment before the onset of potentially irreversible vital organ pathology is ideal. Asymptomatic children with Fabry mutations should be followed closely for the development of renal, cardiac, neurological, or gastrointestinal signs, symptoms, or laboratory changes, which would warrant treatment initiation. A comprehensive care plan should be implemented by the treating physicians to guide the management of children with Fabry disease.

Original languageEnglish (US)
Pages (from-to)104-113
Number of pages10
JournalMolecular Genetics and Metabolism
Volume117
Issue number2
DOIs
StatePublished - Feb 1 2016

Fingerprint

Fabry Disease
Kidney
Hypohidrosis
Therapeutics
Pediatrics
Biopsy
Signs and Symptoms
Pathology
Heart Diseases
Consensus
Guidelines
Physicians
Pain
Mutation
Population

Keywords

  • Children
  • Enzyme replacement therapy
  • Fabry disease
  • Management
  • Treatment

Cite this

Hopkin, R. J., Jefferies, J. L., Laney, D. A., Lawson, V. H., Mauer, M., Taylor, M. R., & Wilcox, W. R. (2016). The management and treatment of children with Fabry disease: A United States-based perspective. Molecular Genetics and Metabolism, 117(2), 104-113. https://doi.org/10.1016/j.ymgme.2015.10.007

The management and treatment of children with Fabry disease : A United States-based perspective. / Hopkin, Robert J.; Jefferies, John L.; Laney, Dawn A.; Lawson, Victoria H.; Mauer, Michael; Taylor, Matthew R.; Wilcox, William R.

In: Molecular Genetics and Metabolism, Vol. 117, No. 2, 01.02.2016, p. 104-113.

Research output: Contribution to journalReview article

Hopkin, Robert J. ; Jefferies, John L. ; Laney, Dawn A. ; Lawson, Victoria H. ; Mauer, Michael ; Taylor, Matthew R. ; Wilcox, William R. / The management and treatment of children with Fabry disease : A United States-based perspective. In: Molecular Genetics and Metabolism. 2016 ; Vol. 117, No. 2. pp. 104-113.
@article{646cc31529d84051a06cd91ec52ddf92,
title = "The management and treatment of children with Fabry disease: A United States-based perspective",
abstract = "Fabry disease is an inherited X-linked disorder that presents during childhood in male and female patients. Young patients may initially experience pain, hypohidrosis, and gastrointestinal symptoms. Other manifestations of Fabry disease, such as renal and cardiac disease, manifest later in adolescence or adulthood. In the pediatric population, renal damage is typically subclinical and identifiable only through biopsy. Specialists from the United States with expertise in Fabry disease convened during 2013-2014 in order to develop these consensus guidelines about the management and treatment of children with Fabry disease. The presence of symptoms in boys and girls of any age is an indication to begin therapy. Early treatment before the onset of potentially irreversible vital organ pathology is ideal. Asymptomatic children with Fabry mutations should be followed closely for the development of renal, cardiac, neurological, or gastrointestinal signs, symptoms, or laboratory changes, which would warrant treatment initiation. A comprehensive care plan should be implemented by the treating physicians to guide the management of children with Fabry disease.",
keywords = "Children, Enzyme replacement therapy, Fabry disease, Management, Treatment",
author = "Hopkin, {Robert J.} and Jefferies, {John L.} and Laney, {Dawn A.} and Lawson, {Victoria H.} and Michael Mauer and Taylor, {Matthew R.} and Wilcox, {William R.}",
year = "2016",
month = "2",
day = "1",
doi = "10.1016/j.ymgme.2015.10.007",
language = "English (US)",
volume = "117",
pages = "104--113",
journal = "Molecular Genetics and Metabolism",
issn = "1096-7192",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - The management and treatment of children with Fabry disease

T2 - A United States-based perspective

AU - Hopkin, Robert J.

AU - Jefferies, John L.

AU - Laney, Dawn A.

AU - Lawson, Victoria H.

AU - Mauer, Michael

AU - Taylor, Matthew R.

AU - Wilcox, William R.

PY - 2016/2/1

Y1 - 2016/2/1

N2 - Fabry disease is an inherited X-linked disorder that presents during childhood in male and female patients. Young patients may initially experience pain, hypohidrosis, and gastrointestinal symptoms. Other manifestations of Fabry disease, such as renal and cardiac disease, manifest later in adolescence or adulthood. In the pediatric population, renal damage is typically subclinical and identifiable only through biopsy. Specialists from the United States with expertise in Fabry disease convened during 2013-2014 in order to develop these consensus guidelines about the management and treatment of children with Fabry disease. The presence of symptoms in boys and girls of any age is an indication to begin therapy. Early treatment before the onset of potentially irreversible vital organ pathology is ideal. Asymptomatic children with Fabry mutations should be followed closely for the development of renal, cardiac, neurological, or gastrointestinal signs, symptoms, or laboratory changes, which would warrant treatment initiation. A comprehensive care plan should be implemented by the treating physicians to guide the management of children with Fabry disease.

AB - Fabry disease is an inherited X-linked disorder that presents during childhood in male and female patients. Young patients may initially experience pain, hypohidrosis, and gastrointestinal symptoms. Other manifestations of Fabry disease, such as renal and cardiac disease, manifest later in adolescence or adulthood. In the pediatric population, renal damage is typically subclinical and identifiable only through biopsy. Specialists from the United States with expertise in Fabry disease convened during 2013-2014 in order to develop these consensus guidelines about the management and treatment of children with Fabry disease. The presence of symptoms in boys and girls of any age is an indication to begin therapy. Early treatment before the onset of potentially irreversible vital organ pathology is ideal. Asymptomatic children with Fabry mutations should be followed closely for the development of renal, cardiac, neurological, or gastrointestinal signs, symptoms, or laboratory changes, which would warrant treatment initiation. A comprehensive care plan should be implemented by the treating physicians to guide the management of children with Fabry disease.

KW - Children

KW - Enzyme replacement therapy

KW - Fabry disease

KW - Management

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=84957881411&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84957881411&partnerID=8YFLogxK

U2 - 10.1016/j.ymgme.2015.10.007

DO - 10.1016/j.ymgme.2015.10.007

M3 - Review article

C2 - 26546059

AN - SCOPUS:84957881411

VL - 117

SP - 104

EP - 113

JO - Molecular Genetics and Metabolism

JF - Molecular Genetics and Metabolism

SN - 1096-7192

IS - 2

ER -